Follow Us
© 2026 Arizent. All rights reserved.
Koster is a Los Angeles-based freelance writer and former Employee Benefit News online managing editor.
For reprint and licensing requests for this article, click here.
To truly flip the script on metabolic disease, benefit leaders must build a cost-efficient, supportive plan for employees and their business.
When GLP-1s are offered without expert clinical and lifestyle support, they lose effectiveness and lead to wasted money.
Through digital health company eMed, Brady, its chief wellness officer, and CEO Linda Yaccarino designed a fixed-cost program for GLP-1 medication and clinical services.
Novo Nordisk will cut prices for Ozempic and Wegovy by up to 50% next year, prompting employers to plan for rising use and manage benefits costs.
Expanded access to mental health, medication, tech-based care and bereavement leave further cover popular and pressing needs.
